Brii Biosciences>   Ankang Li
Ankang Li
Ankang Li is a corporate attorney with 16.2 years of experience in mergers and acquisitions, finance, and the pharmaceutical industry. He has expertise in corporate law, capital markets, and investment banking. Ankang Li has worked at Brii Biosciences in various roles, including CFO, CSO, and Executive Director. He also served as the Chief Financial Officer at Terns Pharmaceuticals and the Chief Financial Officer at Xinhua Pharmaceuticals. Ankang Li is a dedicated professional with a strong background in corporate governance and business development. He is currently based in Shanghai, China. .Read More

Ankang Li Contact information

Add to List
Sequence
Dialer

Ankang Li Current Workspace

Angela Work Summary

Number of Companies worked For
14
Average duration at company ( Year )
1
Number of job Positions
11

About Ankang Li

Corporate attorney with extensive experience in M&A, PE and VC transactions. Admitted to the Bar of the State of New York. Passed CFA level II exam. .Read More

Ankang Li’s Activities

Breaking many records and definitely gonna save many lives .Read More
March 20 2022
Show all activites

Ankang Li's Current Workspace

Brii Biosciences
Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK. .Read More

Ankang Li's Work Experiance

  • Chief Financial Officer | Chief Strategy Officer | Executive Director2022-09-01 - Present
    Brii Biosciences is a biotechnology company developing therapies to address some of the world’s most common public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases and central nervous system diseases, we have built a robust pipeline of potential treatment options based on patient insights and experiences, and are advancing these differentiated investigational therapies to address patient choice. Led by a visionary and experienced leadership team, Brii Bio has deep scientific expertise and a proven ability to progress therapeutic assets from discovery to commercial approval on a consolidated timeline. Established in 2018, Brii Bio now has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. On July 13, 2021, the Company was officially listed on the Hong Kong Stock Exchange under the stock code 2137.HK.